Kharga

Type 2 diabetes mellitus (DM) is a growing health concern with over 460 million people affected worldwide. This research aims to better understand the variety and patterns of other chronic health conditions, called comorbidities, that often occur alongside type 2 diabetes. The study focuses on how these additional conditions vary among patients and change over time, which could help improve personalized care and treatment approaches. Participants will undergo several diagnostic tests and procedures to assess their health status. These include blood tests for HBA1C, lipid profiles, thyroid hormone levels, kidney function, and blood counts. Urine samples will be collected to check kidney health, and imaging tests like echocardiography, ultrasound, and electrocardiograms will be performed when needed. These evaluations help identify the presence of various comorbid conditions such as heart disease, kidney disease, and others. During the study, researchers will gather detailed information about participants' health, including the presence of conditions like hypertension, dyslipidemia, diabetic kidney and eye diseases, stroke, liver disease, infections, and cancer. This information will be collected at the time of inclusion and used to analyze the complexity and variation of comorbidities in people with type 2 diabetes. The study includes adults aged 18 to 90 years with type 2 diabetes, and results may guide more comprehensive care planning in the future.

Type 2 diabetes mellitus (T2DM) is a widespread condition affecting millions worldwide, caused by insulin resistance and reduced insulin secretion. This research explores the relationship between red cell distribution width (RDW), a measure of red blood cell size variation, and HbA1C levels in patients with T2DM before and after achieving better blood sugar control. The study aims to clarify inconsistent findings about how RDW relates to T2DM and its complications, which include kidney, nerve, and heart diseases. Participants will undergo blood tests to measure RDW, HbA1C, and lipid profiles at the start of the study. For one group, these tests will be repeated after three and six months to observe changes following glycemic control. The study monitors these blood markers to evaluate their correlation and potential use in tracking diabetes progression and treatment response. During the study, participants will have blood drawn at specified times to assess their HbA1C, RDW, and lipid levels. Researchers will analyze these results to understand how RDW relates to blood sugar control over time. The primary outcome is the correlation between RDW and HbA1C at inclusion, three months, and six months. The study involves careful monitoring to support better management of T2DM and its associated risks.